NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea
· Delayed Price · Currency is KRW 640.00
+24.00 (3.90%)
At close: Dec 5, 2025
NeoImmuneTech Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 57,817 | 34,172 | 68,739 | 115,630 | 154,250 | 71,217 | Upgrade
|
| Short-Term Investments | 13,617 | 663.25 | 333.38 | 1,445 | 220.29 | 0.9 | Upgrade
|
| Cash & Short-Term Investments | 71,434 | 34,835 | 69,072 | 117,075 | 154,471 | 71,218 | Upgrade
|
| Cash Growth | 76.51% | -49.57% | -41.00% | -24.21% | 116.90% | -34.08% | Upgrade
|
| Accounts Receivable | 12.13 | 20.37 | - | - | - | - | Upgrade
|
| Receivables | 12.13 | 20.37 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 2,779 | 4,446 | - | 895.8 | - | - | Upgrade
|
| Other Current Assets | - | 33.87 | 3,185 | -0 | 12,252 | 9,414 | Upgrade
|
| Total Current Assets | 74,225 | 39,335 | 72,257 | 117,971 | 166,722 | 80,632 | Upgrade
|
| Property, Plant & Equipment | 4,720 | 6,771 | 7,749 | 9,397 | 9,056 | 4,058 | Upgrade
|
| Other Intangible Assets | 8,519 | 6,461 | 6,168 | 6,554 | 6,591 | 6,471 | Upgrade
|
| Other Long-Term Assets | 919.71 | 12,858 | 4,338 | 5,944 | 4,659 | 4,484 | Upgrade
|
| Total Assets | 88,384 | 65,426 | 90,511 | 139,865 | 187,027 | 95,645 | Upgrade
|
| Accrued Expenses | 5,289 | 6,316 | 7,717 | 12,945 | 17,426 | 7,493 | Upgrade
|
| Short-Term Debt | 8,477 | 6,935 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 913.63 | 1,150 | 1,353 | 1,279 | 1,284 | 545.01 | Upgrade
|
| Current Income Taxes Payable | -60.32 | - | - | 92.49 | 59.33 | 21.63 | Upgrade
|
| Other Current Liabilities | 5,850 | 6,385 | 3,816 | 2,080 | 1,642 | 938.61 | Upgrade
|
| Total Current Liabilities | 20,470 | 20,785 | 12,886 | 16,397 | 20,411 | 8,998 | Upgrade
|
| Long-Term Leases | 2,119 | 2,686 | 2,555 | 3,572 | 4,511 | 2,360 | Upgrade
|
| Pension & Post-Retirement Benefits | 177.78 | 257.11 | 151.69 | 142.43 | - | 59.45 | Upgrade
|
| Other Long-Term Liabilities | 45.62 | 36.29 | 62.24 | 64.34 | 63.09 | 0 | Upgrade
|
| Total Liabilities | 22,813 | 23,764 | 15,655 | 20,176 | 24,985 | 11,418 | Upgrade
|
| Common Stock | 4.61 | 2.91 | 2.55 | 2.51 | 2.34 | 1.8 | Upgrade
|
| Additional Paid-In Capital | 368,628 | 337,199 | 295,772 | 290,644 | 271,282 | 142,448 | Upgrade
|
| Retained Earnings | -331,173 | -325,185 | -246,517 | -190,424 | -122,781 | -62,771 | Upgrade
|
| Comprehensive Income & Other | 28,111 | 29,645 | 25,599 | 19,466 | 13,539 | 4,547 | Upgrade
|
| Shareholders' Equity | 65,571 | 41,662 | 74,856 | 119,689 | 162,042 | 84,227 | Upgrade
|
| Total Liabilities & Equity | 88,384 | 65,426 | 90,511 | 139,865 | 187,027 | 95,645 | Upgrade
|
| Total Debt | 11,510 | 10,771 | 3,908 | 4,851 | 5,795 | 2,905 | Upgrade
|
| Net Cash (Debt) | 59,924 | 24,064 | 65,164 | 112,224 | 148,676 | 68,312 | Upgrade
|
| Net Cash Growth | 65.17% | -63.07% | -41.93% | -24.52% | 117.64% | -35.08% | Upgrade
|
| Net Cash Per Share | 187.36 | 243.40 | 659.23 | 1136.26 | 1560.75 | 826.59 | Upgrade
|
| Filing Date Shares Outstanding | 108.36 | 494.34 | 494.34 | 494.14 | 492.91 | 413.63 | Upgrade
|
| Total Common Shares Outstanding | 108.36 | 494.34 | 494.34 | 494.14 | 492.91 | 413.63 | Upgrade
|
| Working Capital | 53,755 | 18,550 | 59,371 | 101,574 | 146,311 | 71,633 | Upgrade
|
| Book Value Per Share | 605.13 | 84.28 | 151.43 | 242.22 | 328.75 | 203.63 | Upgrade
|
| Tangible Book Value | 57,052 | 35,200 | 68,689 | 113,136 | 155,452 | 77,756 | Upgrade
|
| Tangible Book Value Per Share | 526.51 | 71.21 | 138.95 | 228.96 | 315.38 | 187.99 | Upgrade
|
| Machinery | 4,510 | 6,530 | 5,727 | 4,864 | 3,027 | 1,307 | Upgrade
|
| Construction In Progress | - | - | - | - | 764.66 | 46.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.